Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women

Pharmacogenetics

Volumn 13, Issue 10, 2003, Pages 595-606

  Floyd, Michael D ^a   Gervasini, Guillermo ^a   Masica, Andrew L ^a   Mayo, Gail ^a   George Jr , Alfred L ^a   Bhat, Kolari ^a   Kim, Richard B ^a   Wilkinson, Grant R ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CYP3A; CYP3A4* 1B; CYP3A5* 3; CYP3A5* 6; CYP3A5* 7; Midazolam; Polymorphisms

Indexed keywords

CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; ERYTHROMYCIN; MIDAZOLAM; RIFAMPICIN;

ADULT; AFRICA; ALLELE; ARTICLE; BREATH ANALYSIS; CONTROLLED STUDY; DNA DETERMINATION; DNA POLYMORPHISM; DNA SEQUENCE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG METABOLISM; ENZYME ACTIVITY; EUROPE; EXON; FEMALE; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; HOMOZYGOSITY; HUMAN; HUMAN EXPERIMENT; INTESTINE; LIVER; MALE; NORMAL HUMAN; POLYMERASE CHAIN REACTION; POPULATION RESEARCH; PRIORITY JOURNAL; WILD TYPE;

ADOLESCENT; ADULT; AFRICAN AMERICANS; ANTI-ANXIETY AGENTS; AREA UNDER CURVE; BREATH TESTS; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; ERYTHROMYCIN; EUROPEAN CONTINENTAL ANCESTRY GROUP; EXONS; FEMALE; GENOTYPE; HOMOZYGOTE; HUMANS; INTESTINES; LIVER; MALE; METABOLIC CLEARANCE RATE; MIDAZOLAM; MIDDLE AGED; PHENOTYPE; POLYMORPHISM, GENETIC; RIFAMPIN; VARIATION (GENETICS);

EID: 0142250945     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-200310000-00003     Document Type: Article

References (62)

1. Westlind A, Malmebo S, Johansson I, Otter C, Andersson TB, Ingelman-Sundberg M, et al. Cloning and tissue distribution of a novel human cytochrome P450 of the CYP3A subfamily, CYP3A43. Biochem Biophys Res Commun 2001; 281:1349-1355.
2. Gellner K, Eiselt R, Hustert E, Arnold H, Koch I, Haberl M, et al. Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene. Pharmacogenetics 2001; 11:111-121.
3. Komori M, Nishio K, Kitada M, Shiramatsu K, Muroya K, Soma M, et al. Fetus-specific expression of a form of cytochrome P-450 in human livers. Biochemistry 1990; 29:4430-4433.
4. Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K, et al. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos 2002; 30:883-891.
5. Thummel KE, Wilkinson GR. In vitro and in vivo drug interactions involving human CYP3A. Ann Rev Pharmacol Toxicol 1998; 38: 389-430.
6. Özdemir V, Kalow W, Tang BK, Paterson AD, Walker SE, Endrenyi L, et al. Evaluation of the genetic component of variability of CYP3A4 activity: a repeated drug administration method. Pharmacogenetics 2000; 10:373-388.
7. Bertilsson L. Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet 1995; 29:192-209.
8. Lin YS, Lockwood GF, Graham MA, Brian WR, Loi CM, Dobrinska MR, et al. In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration. Pharmacogenetics 2001; 11:781-791.
9. Paris PL, Kupelian PA, Hall JM, Williams TL, Levin H, Klein EA, et al. Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients. Cancer Epidemiol Biomarkers Prev 1999; 8:901-905.
10. Ball SE, Scantina J, Kao J, Ferron GM, Fruncillo R, Mayer P, et al. Population distribution and effects on drug metabolism of a genetic variant in the 5′ promoter region of CYP3A4. Clin Pharmacol Ther 1999; 66:288-294.
11. Rebbeck TR, Jaffe JM, Walker AH, Wein AJ, Malkowicz SB. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 1998; 90:1225-1229.
12. Felix CA, Walker AH, Lange BJ, Williams TM, Winick NJ, Cheung NK, et al. Association of CYP3A4 genotype with treatment-related leukemia. Proc Natl Acad Sci 1998; 95:13176-13181.
13. Wandel C, Witte JS, Hall JM, Stein CM, Wood AJJ, Wilkinson GR. CYP3A activity in African American and European men: population differences and functional effect of the CYP3A4* 1B 5′-promoter region polymorphism. Clin Pharmacol Ther 2000; 68:82-91.
14. Spurdle AB, Goodwin B, Hodgson E, Hopper JL, Chen X, Purdie DM, et al. The CYP3A4* 1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer. Pharmacogenetics 2002; 12:355-366.
15. Westlind A, Löfberg L, Tindberg N, Andersson TB, Ingelman-Sundberg M. Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphisms in the 5′-upstream regulatory region. Biochem Biophys Res Commmun 1999; 259:201-205.
16. Kittles RA, Chen W, Panguluri RK, Ahaghotu C, Jackson A, Adebamowo CA, et al. CYP3A4-V and prostate cancer in African Americans: casual or confounding association because of population stratification? Hum Genet 2002; 110:553-560.
17. Blanco JG, Edick MJ, Hancock ML, Winick NJ, Dervieux T, Amylon MD, et al. Genetic polymorphisms in CYP3A5, CYP3A4 and NQO1 in children who developed therapy-related myeloid malignancies. Pharmacogenetics 2002; 12:605-611.
18. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nature Genet 2001; 4:383-391.
19. Lin YS, Dowling AL, Quigley SD, Farin FM, Zhang J, Lamba J, et al. Co-regulation of CYP3A4 and CYP3A5 and contribution of hepatic and intestinal midazolam metabolism. Mol Pharmacol 2002; 62:162-172.
20. Wrighton SA, Ring BJ, Watkins PB, VandenBraden M. Identification of a polymorphically expressed member of the human cytochrome P-450III family. Mol Pharmacol 1989; 36:97-105.
21. Schuetz EG, Schuetz JD, Strom SC, Thompson MT, Fisher RA, Molowa DT, et al. Regulation of human liver cytochromes P-450 in family 3A in primary and continuous culture of human hepatocytes. Hepatology 1993; 18:1254-1262.
22. Rae JM, Johnson MD, Lippman ME, Flockart DA. Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays. J Pharmacol Exp Ther 2001; 299:849-857.
23. Schuetz EG, Schinkel AH, Relling MV, Schuetz JD. P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans. Proc Natl Acad Sci 1996; 93:4001-4005.
24. Cascorbi I, Gerloff T, Johne A, Meisel C, Hoffmeyer S, Schwab M, et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 2001; 69:169-174.
25. Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001; 70:189-199.
26. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmöller J, Cascorbi I, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci 2000; 97:3473-3478.
27. Kinirons MT, O'Shea D, Downing TE, Fitzwilliam AT, Joellenbeck L, Groopman JD, et al. Absence of correlations among three putative in vivo probes of human cytochrome P4503A activity in young healthy men. Clin Pharmacol Ther 1993; 54:621-629.
28. Dresser GK, Schwarz UI, Wilkinson GR, Kim RB. Coordinate induction of both CYP3A and MDR1 by St. John's wort in healthy subjects. Clin Pharmacol Ther 2003; 73:41-50.
29. Rogers JF, Rocci ML Jr, Haughey DB, Bertino JS Jr. An evaluation of the suitability of intravenous midazolam as an in vivo marker for hepatic cytochrome P4503A activity. Clin Pharmacol Ther 2003; 73:153-158.
30. Poland RA, Lin K-M, Nuccio C, Wilkinson GR. Cytochrome P4502E1 and 3A activities do not differ between Mexicans and European Americans. Clin Pharmacol Ther 2002; 72:288-293.
31. Tateishi T, Watanabe M, Nakura H, Asoh M, Shirai H, Mizorogi Y, et al. CYP3A activity in European American and Japanese men using midazolam as an in vivo probe. Clin Pharmacol Ther 2001; 69:333-339.
32. Lamba JK, Lin YS, Schuetz EG, Thummel KE. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 2002; 54:1271-1294.
33. Bornemann LD, Min BH, Crews T, Rees MMC, Blumenthal HP, Colburn WA, et al. Dose dependent pharmacokinetics of midazolam. Eur J Clin Pharm 1985; 29:91-95.
34. Harris RZ, Benet LZ, Schwartz JB. Gender effects in pharmacokinetics and pharmacodynamics. Drugs 1995; 50:222-239.
35. Meibohm B, Beierle I, Derendorf H. How important are gender differences in pharmacokinetics? Clin Pharmacokinet 2002; 41:329-342.
36. Cummins CL, Wu C-Y, Benet LZ. Sex-related differences in the clearance of cytochrome P450 3A4 substrates may be caused by P-glycoprotein. Clin Pharmacol Ther 2002; 72:474-489.
37. Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, et al. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res 1999; 16:408-414.
38. Holazo AA, Winkler MB, Patel IH. Effects of age, gender and oral contraceptives on intramuscular midazolam pharmacokinetics. J Clin Pharmacol 1998; 28:1040-1045.
39. Greenblatt DJ, Abernethy DR, Locniskar A, Harmatz JS, Limjuco RA, Shader RI. Effect of age, gender, and obesity on midazolam kinetics. Anesthesiology 1984; 61:27-35.
40. Thummel KE, O'Shea D, Paine MF, Shen DD, Kunze KL, Perkins JD, et al. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther 1996; 59:491-502.
41. Koch I, Weil R, Wolbold R, Bröckmoller J, Hustert E, Burk O, et al. Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. Drug Metab Dispos 2002; 30: 1108-1114.
42. Westlind-Johnsson A, Malmebo S, Johansson A, Otter C, Andersson TB, Johansson I, et al. Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. Drug Metab Disp 2003; 31:755-761.
43. Kronbach T, Mathys D, Umeno M, Gonzalez FJ, Meyer UA. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol 1989; 36:89-96.
44. Gorski JC, Hall SD, Jones DR, VandenBranden M, Wrighton SA. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol 1994; 47:1643-1653.
45. Maenpaa J, Hall SD, Ring BJ, Strom SC, Wrighton SA. Human cytochrome P450 3A (CYP3A) mediated midazolam metabolism: the effect of assay conditions and regioselective stimulation by α-naphthoflavone, terfenadine and testosterone. Pharmacogenetics 1998; 8: 137-155.
46. Shih P-S, Huang J-D. Pharmacokinetics of midazolam and 1′-hydroxymidazolam in Chinese with different CYP3A5 genotypes. Drug Metab Disp 2002; 30:1491-1496.
47. Rekka E, Evdokimova E, Eeckhoudt S, Labar G, Calderon PB. Role of temperature on protein and mRNA cytochrome P450 3A (CYP3A) isozymes expression and midazolam oxidation by cultured rat precision-cut liver slices. Biochem Pharmacol 2002; 64:633-643.
48. Goodwin B, Redinbo MR, Kliewer SA. Regulation of CYP3A gene transcription by the pregnane X receptor. Annu Rev Pharmacol Toxicol 2002; 42:1-23.
49. Goodwin B, Hodgson E, Liddle C. The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. Mol Pharmacol 1999; 56: 1329-1339.
50. Ged C, Rouillon M, Pichard L, Combalbert J, Bressot N, Bories P. The increase in urinary excretion of 6β-hydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction. Br J Clin Pharmac 1989; 28:373-387.
51. Watkins PB, Murray SA, Winkelman LG, Heuman DM, Wrighton SA, Guzelian PS. Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. Studies in rats and patients. J Clin Invest 1989; 83:688-697.
52. 14C N-methyl] erythromycin breath test in healthy male volunteers. J Clin Pharmacol 1998; 38:492-495.
53. Polk RE, Brophy DF, Israel DS, Patron R, Sadler BM, Chittick GE, et al. Pharmacokinetic interaction between amprenavir and rifabutin or rifampin in healthy males. Antimicrob Agents Chemother 2001; 45:502-508.
54. Eeckhoudt SL, Desager JP, Robert AR, Leclercq I, Verbeeck RK, Horsmans Y. Midazolam and cortisol metabolism before and after CYP3A induction in humans. Int J Clin Pharmacol Ther 2001; 39:293-299.
55. Backman JT, Olkkola KT, Neuvonen PJ. Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clin Pharmacol Ther 1996; 59:7-13.
56. Backman JT, Kivistö KT, Olkkola KT, Neuvonen PJ. The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. Eur J Clin Pharmacol 1998; 54:53-58.
57. Wang Z, Gorski JC, Hamman MA, Huang S-M, Lesko LJ, Hall SD. The effects of St. John's wort (Hypericum perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther 2001; 70:317-326.
58. Gorski JC, Jones DR, Haehner-Daniels BD, Hamman MA, O'Mara EM, Hall SD. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin Pharmacol Ther 1998; 64:133-144.
59. Lan L-B, Dalton JT, Schuetz EG. Mdr1 limits CYP3A metabolism in vivo. Mol Pharmacol 2000; 58:863-869.
60. Kim RB. MDR1 single nucleotide polymorphisms: multiplicity of haplotypes and functional consequences. Pharmacogenetics 2002; 12: 425-427.
61. Zhang J, Kuehl P, Green ED, Touchman JW, Watkins PB, Daly A, et al. The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. Pharmacogenetics 2001; 11:555-571.
62. Hustert E, Zibat A, Presecan-Siedel E, Eiselt R, Mueller R, Fuss C, et al. Natural protein variants of pregnane X receptor with altered transactivation activity toward CYP3A4. Drug Metab Disp 2001; 29:1454-1459.